JP2015534982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534982A5 JP2015534982A5 JP2015538060A JP2015538060A JP2015534982A5 JP 2015534982 A5 JP2015534982 A5 JP 2015534982A5 JP 2015538060 A JP2015538060 A JP 2015538060A JP 2015538060 A JP2015538060 A JP 2015538060A JP 2015534982 A5 JP2015534982 A5 JP 2015534982A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- hiv
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000036436 anti-hiv Effects 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 210000004748 cultured cell Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims 2
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940125777 fusion inhibitor Drugs 0.000 claims 1
- 229940124524 integrase inhibitor Drugs 0.000 claims 1
- 239000002850 integrase inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261715642P | 2012-10-18 | 2012-10-18 | |
| US61/715,642 | 2012-10-18 | ||
| PCT/US2013/065696 WO2014063059A1 (en) | 2012-10-18 | 2013-10-18 | Broadly-neutralizing anti-hiv antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018243618A Division JP6732872B2 (ja) | 2012-10-18 | 2018-12-26 | 広域中和抗ｈｉｖ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015534982A JP2015534982A (ja) | 2015-12-07 |
| JP2015534982A5 true JP2015534982A5 (enExample) | 2016-08-25 |
| JP6461804B2 JP6461804B2 (ja) | 2019-01-30 |
Family
ID=50488789
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538060A Active JP6461804B2 (ja) | 2012-10-18 | 2013-10-18 | 広域中和抗ｈｉｖ抗体 |
| JP2018243618A Active JP6732872B2 (ja) | 2012-10-18 | 2018-12-26 | 広域中和抗ｈｉｖ抗体 |
| JP2020117726A Active JP7076722B2 (ja) | 2012-10-18 | 2020-07-08 | 広域中和抗ｈｉｖ抗体 |
| JP2022075767A Active JP7376898B2 (ja) | 2012-10-18 | 2022-05-02 | 広域中和抗ｈｉｖ抗体 |
| JP2023180055A Active JP7681278B2 (ja) | 2012-10-18 | 2023-10-19 | 広域中和抗ｈｉｖ抗体 |
| JP2025075098A Pending JP2025118727A (ja) | 2012-10-18 | 2025-04-30 | 広域中和抗ｈｉｖ抗体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018243618A Active JP6732872B2 (ja) | 2012-10-18 | 2018-12-26 | 広域中和抗ｈｉｖ抗体 |
| JP2020117726A Active JP7076722B2 (ja) | 2012-10-18 | 2020-07-08 | 広域中和抗ｈｉｖ抗体 |
| JP2022075767A Active JP7376898B2 (ja) | 2012-10-18 | 2022-05-02 | 広域中和抗ｈｉｖ抗体 |
| JP2023180055A Active JP7681278B2 (ja) | 2012-10-18 | 2023-10-19 | 広域中和抗ｈｉｖ抗体 |
| JP2025075098A Pending JP2025118727A (ja) | 2012-10-18 | 2025-04-30 | 広域中和抗ｈｉｖ抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10047146B2 (enExample) |
| EP (2) | EP3783018A1 (enExample) |
| JP (6) | JP6461804B2 (enExample) |
| CN (3) | CN118955699A (enExample) |
| AU (4) | AU2013331049B2 (enExample) |
| BR (1) | BR112015008635B1 (enExample) |
| CA (2) | CA3236192A1 (enExample) |
| CY (1) | CY1124405T1 (enExample) |
| DK (1) | DK2908912T3 (enExample) |
| EA (2) | EA035012B1 (enExample) |
| ES (1) | ES2822135T3 (enExample) |
| HR (1) | HRP20201505T1 (enExample) |
| HU (1) | HUE051577T2 (enExample) |
| IL (5) | IL285049B (enExample) |
| LT (1) | LT2908912T (enExample) |
| MX (2) | MX376969B (enExample) |
| PL (1) | PL2908912T3 (enExample) |
| PT (1) | PT2908912T (enExample) |
| SI (1) | SI2908912T1 (enExample) |
| WO (1) | WO2014063059A1 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA026557B1 (ru) | 2008-12-09 | 2017-04-28 | Джилид Сайэнс, Инк. | Промежуточные соединения для получения модуляторов толл-подобных рецепторов |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| SI3590949T1 (sl) | 2010-10-01 | 2022-09-30 | Modernatx, Inc. | Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| HUE053545T2 (hu) | 2011-05-17 | 2021-07-28 | Univ Rockefeller | Humán immundeficiencia vírus semlegesítõ antitestek és eljárások alkalmazásukra |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| RU2649364C2 (ru) | 2011-12-16 | 2018-04-02 | Модерна Терапьютикс, Инк. | Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты |
| EP3520821A1 (en) | 2012-04-02 | 2019-08-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| BR112015008635B1 (pt) * | 2012-10-18 | 2023-10-31 | The Rockefeller University | Anticorpos anti-hiv amplamente neutralizantes |
| SI2922554T1 (sl) | 2012-11-26 | 2022-06-30 | Modernatx, Inc. | Terminalno modificirana RNA |
| AU2014224049B2 (en) * | 2013-02-28 | 2018-11-29 | Therabiol, Inc. | HIV antigens and antibodies |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| US10093720B2 (en) * | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
| PT3166607T (pt) * | 2014-07-11 | 2022-12-07 | Gilead Sciences Inc | Moduladores de receptores de tipo toll para o tratamento do vih |
| AU2015318061B2 (en) | 2014-09-16 | 2018-05-17 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
| US20170267784A1 (en) | 2014-10-23 | 2017-09-21 | Singh Molecular Medicine, Llc | Single domain antibodies directed against intracellular antigens |
| WO2016149698A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies) |
| WO2017053906A1 (en) * | 2015-09-24 | 2017-03-30 | Abvitro Llc | Hiv antibody compositions and methods of use |
| TWI746473B (zh) * | 2015-11-02 | 2021-11-21 | 美商辛分子醫藥有限公司 | 針對細胞內抗原之單域抗體 |
| US20190328900A1 (en) | 2016-07-01 | 2019-10-31 | Glaxosmithkline Intellectual Property Development Limited | Antibody-drug conjugates and therapeutic methods using the same |
| WO2018075564A1 (en) | 2016-10-17 | 2018-04-26 | University Of Maryland, College Park | Multispecific antibodies targeting human immunodeficiency virus and methods of using the same |
| EP4613776A3 (en) | 2016-10-21 | 2025-11-26 | Altor BioScience Corporation | Multimeric il-15-based molecules |
| EP3562505A4 (en) * | 2016-12-27 | 2020-11-11 | The Rockefeller University | HIGHLY NEUTRALIZING ANTI-HIV-1 ANTIBODIES AND THEIR USE PROCEDURE |
| SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| EP3755713A1 (en) * | 2018-02-21 | 2020-12-30 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 env and their use |
| CN112334572A (zh) | 2018-06-19 | 2021-02-05 | 南特细胞公司 | Hiv治疗组合物和方法 |
| US11168130B2 (en) | 2018-07-03 | 2021-11-09 | Gilead Sciences, Inc. | Antibodies that target HIV GP120 and methods of use |
| US20210292396A1 (en) * | 2018-07-27 | 2021-09-23 | International Aids Vaccine Initiative | Enginerred antibodies to hiv env |
| EP3849612A4 (en) | 2018-09-14 | 2022-07-06 | The Rockefeller University | ANTI-HIV ANTIBODIES 10-1074 VARIANTS |
| JP7641223B2 (ja) * | 2019-01-28 | 2025-03-06 | サイフォス、バイオサイエンシズ、インコーポレイテッド | Ｃａｒ細胞上の非天然ｎｋｇ２ｄ受容体に、結合した異種分子を選択的に送達する改変非天然ｎｋｇ２ｄリガンド |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| HUE059677T2 (hu) | 2019-03-22 | 2022-12-28 | Gilead Sciences Inc | Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása |
| US20220185870A1 (en) * | 2019-04-04 | 2022-06-16 | Vanderbilt University | Hiv/hcv cross-reactive antibodies and uses thereof |
| TWI762925B (zh) | 2019-05-21 | 2022-05-01 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
| CN114245807B (zh) | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| KR20220047277A (ko) | 2019-07-16 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| CN112759651B (zh) * | 2019-11-01 | 2022-09-20 | 北京华夏清医治疗科技有限公司 | 一种包含嵌合抗原受体修饰的t细胞及其应用 |
| EP3831848A1 (en) * | 2019-12-02 | 2021-06-09 | Universität zu Köln | Broadly neutralizing antibodies against hiv |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| EP4153181A1 (en) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| BR112023002164A2 (pt) | 2020-08-07 | 2023-03-14 | Gilead Sciences Inc | Profármacos de análogos de nucleotídeos de fosfonamida e seu uso farmacêutico |
| CN116157416A (zh) | 2020-08-25 | 2023-05-23 | 吉利德科学公司 | 靶向hiv的多特异性抗原结合分子及其使用方法 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CA3195799A1 (en) | 2020-11-11 | 2022-05-19 | Stephen R. Martin | Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7736929B2 (ja) | 2021-12-03 | 2025-09-09 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症のための治療化合物 |
| US12084467B2 (en) | 2021-12-03 | 2024-09-10 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| EP4440702B1 (en) | 2021-12-03 | 2025-05-21 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| MX2024007429A (es) | 2021-12-17 | 2024-09-10 | Viiv Healthcare Co | Terapias de combinacion para infecciones por vih y usos de las mismas. |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| AU2023307100A1 (en) | 2022-07-12 | 2025-01-02 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| AR132464A1 (es) | 2023-04-19 | 2025-07-02 | Gilead Sciences Inc | Régimen de dosificación de inhibidor de la cápside |
| TW202448483A (zh) | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | 用於ｈｉｖ之治療性化合物 |
| WO2024249573A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Solid forms of compounds useful in the treatment of hiv |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025050404A1 (zh) * | 2023-09-08 | 2025-03-13 | 成都维瑾柏鳌生物医药科技有限公司 | 一种药物组合物及其应用 |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TW202530226A (zh) | 2023-10-11 | 2025-08-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025137245A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250289822A1 (en) | 2024-03-01 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184447A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US81A (en) | 1836-11-15 | Erawijjg | ||
| US6593A (en) | 1849-07-17 | Cutting | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5798251A (en) * | 1990-05-29 | 1998-08-25 | Cedars-Sinai Medical Center | Antibody and antibody derivative immunoreagents reactive with a conserved epitope of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120 |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| CA2207869A1 (en) | 1994-12-02 | 1996-06-06 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| JP2005510201A (ja) | 2001-01-26 | 2005-04-21 | アブジェニックス インコーポレイテッド | Ｈｉｖ−１に対する中和ヒトモノクローナル抗体、それらの産生および使用 |
| WO2003095492A1 (en) * | 2002-05-06 | 2003-11-20 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
| US7501494B2 (en) * | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| CA2521048A1 (en) * | 2003-04-14 | 2004-10-21 | Children's National Medical Center | Anti-retroviral analysis by mass spectrometry |
| US7667006B2 (en) * | 2003-12-16 | 2010-02-23 | Kumamoto Technology And Industry Foundation | Anti-HIV antibody |
| WO2005067646A2 (en) * | 2004-01-07 | 2005-07-28 | Hitachi Chemical Research Center, Inc. | Primers and probes for the detection of hiv |
| JP4895727B2 (ja) * | 2006-08-28 | 2012-03-14 | シスメックス株式会社 | 抗ｈｉｖ抗体検出試薬、試薬キット、試薬の製造方法、及び抗ｈｉｖ抗体の検出方法 |
| US20080279879A1 (en) * | 2006-11-17 | 2008-11-13 | New York University | INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE |
| WO2009015247A2 (en) | 2007-07-23 | 2009-01-29 | Maxygen, Inc. | Chimeric hiv antigens |
| AU2009335688B2 (en) * | 2008-12-19 | 2013-04-18 | Abbott Laboratories | Molecular assay for diagnosis of HIV tropism |
| US20110212106A1 (en) * | 2010-01-20 | 2011-09-01 | Institute For Research In Bioscience | Hiv-1 neutralizing antibodies and uses thereof |
| RU2535034C2 (ru) | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
| PL3556396T3 (pl) | 2010-08-31 | 2022-09-12 | Theraclone Sciences, Inc. | Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv) |
| WO2012074863A2 (en) * | 2010-12-01 | 2012-06-07 | Albert Einstein College Of Medicine Of Yeshiva University | Constructs and methods to identify antibodies that target glycans |
| BR112015008635B1 (pt) | 2012-10-18 | 2023-10-31 | The Rockefeller University | Anticorpos anti-hiv amplamente neutralizantes |
-
2013
- 2013-10-18 BR BR112015008635-7A patent/BR112015008635B1/pt active IP Right Grant
- 2013-10-18 PL PL13847347T patent/PL2908912T3/pl unknown
- 2013-10-18 CN CN202410516500.4A patent/CN118955699A/zh active Pending
- 2013-10-18 LT LTEP13847347.5T patent/LT2908912T/lt unknown
- 2013-10-18 CA CA3236192A patent/CA3236192A1/en active Pending
- 2013-10-18 ES ES13847347T patent/ES2822135T3/es active Active
- 2013-10-18 CN CN202110092787.9A patent/CN112920269B/zh active Active
- 2013-10-18 WO PCT/US2013/065696 patent/WO2014063059A1/en not_active Ceased
- 2013-10-18 EA EA201590741A patent/EA035012B1/ru unknown
- 2013-10-18 AU AU2013331049A patent/AU2013331049B2/en active Active
- 2013-10-18 EP EP20182718.5A patent/EP3783018A1/en active Pending
- 2013-10-18 EP EP13847347.5A patent/EP2908912B1/en active Active
- 2013-10-18 CN CN201380064622.4A patent/CN104918658B/zh active Active
- 2013-10-18 US US14/436,608 patent/US10047146B2/en active Active
- 2013-10-18 HU HUE13847347A patent/HUE051577T2/hu unknown
- 2013-10-18 CA CA2888659A patent/CA2888659C/en active Active
- 2013-10-18 JP JP2015538060A patent/JP6461804B2/ja active Active
- 2013-10-18 DK DK13847347.5T patent/DK2908912T3/da active
- 2013-10-18 SI SI201331809T patent/SI2908912T1/sl unknown
- 2013-10-18 HR HRP20201505TT patent/HRP20201505T1/hr unknown
- 2013-10-18 MX MX2015004924A patent/MX376969B/es active IP Right Grant
- 2013-10-18 EA EA201992107A patent/EA201992107A1/ru unknown
- 2013-10-18 IL IL285049A patent/IL285049B/en unknown
- 2013-10-18 PT PT138473475T patent/PT2908912T/pt unknown
-
2015
- 2015-04-16 IL IL238320A patent/IL238320B/en unknown
- 2015-04-16 MX MX2020011669A patent/MX2020011669A/es unknown
-
2018
- 2018-06-12 US US16/006,420 patent/US10392433B2/en active Active
- 2018-12-26 JP JP2018243618A patent/JP6732872B2/ja active Active
-
2019
- 2019-02-14 AU AU2019201039A patent/AU2019201039B2/en active Active
- 2019-07-10 US US16/507,867 patent/US11142564B2/en active Active
-
2020
- 2020-07-08 JP JP2020117726A patent/JP7076722B2/ja active Active
- 2020-09-28 AU AU2020244391A patent/AU2020244391B2/en active Active
- 2020-10-21 CY CY20201100995T patent/CY1124405T1/el unknown
-
2021
- 2021-09-09 US US17/470,184 patent/US11649276B2/en active Active
-
2022
- 2022-05-02 JP JP2022075767A patent/JP7376898B2/ja active Active
- 2022-05-25 IL IL293362A patent/IL293362B2/en unknown
-
2023
- 2023-02-28 IL IL301018A patent/IL301018B1/en unknown
- 2023-03-29 AU AU2023201926A patent/AU2023201926B2/en not_active Expired - Fee Related
- 2023-04-07 US US18/297,301 patent/US12338277B2/en active Active
- 2023-10-19 JP JP2023180055A patent/JP7681278B2/ja active Active
-
2025
- 2025-04-30 JP JP2025075098A patent/JP2025118727A/ja active Pending
- 2025-05-09 US US19/203,424 patent/US20250320280A1/en active Pending
- 2025-09-15 IL IL323371A patent/IL323371A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015534982A5 (enExample) | ||
| RU2016129274A (ru) | Канинизированные мышиные антитела к человеческому pd-1 | |
| JP2019536806A5 (enExample) | ||
| JP2011528902A5 (enExample) | ||
| JP2012504955A5 (enExample) | ||
| JP2014512809A5 (enExample) | ||
| RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| JP2018535650A5 (enExample) | ||
| JP2010516229A5 (enExample) | ||
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP2018521638A5 (enExample) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| JP2020508303A5 (enExample) | ||
| JP2018035138A5 (enExample) | ||
| HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP2018527952A5 (enExample) | ||
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2015503909A5 (enExample) | ||
| JP2016524463A5 (enExample) | ||
| RU2010120879A (ru) | Антитела против g-белка распираторно-синцитиального вируса (rsv) | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2016507470A5 (enExample) | ||
| JP2025131696A5 (enExample) | ||
| JP2011505867A5 (enExample) |